Lena Biosciences, Inc.
Atlanta, GA
- UEI
- HVWSKPM6NUK3
- CAGE
- 555K1
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 6065 Roswell Rd #420, Atlanta, GA 30328, USA
- Website
- lenabio.com
- Founded
- 2008
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Endomimetics, Inc. | Birmingham, AL | — |
| Neucyte Inc. | Mountain View, CA | 325414 Biological Product (except Diagnostic) Manufacturing |
| Xylyx Bio, Inc. | NY | — |
| Insphero, Inc. | Portland, ME | 325414 Biological Product (except Diagnostic) Manufacturing |
| Biopico Systems Inc. | Irvine, CA | 334510 Electromedical and Electrotherapeutic Apparatus Manufacturing |
About the company
Lena Biosciences, Inc. is a woman-owned small business and manufacturer of goods specializing in advanced biomedical technologies, with a focus on developing innovative microphysiological screening platforms and cell culture systems. The company is registered in SAM.gov and has been actively receiving federal grants since at least 2020, demonstrating expertise in developing sophisticated in vitro testing models for chemical and pharmaceutical research. Their core technological offerings center on creating advanced 3D cell culture scaffolds and microphysiological systems (MPS) that can simulate human biological responses with high fidelity, enabling more precise and efficient toxicity and drug metabolism testing.
The company has secured multiple significant federal grants from civilian agencies, particularly the National Institute of Environmental Health Sciences (NIEHS) and the National Center for Advancing Translational Sciences (NCATS), focusing on developing cutting-edge screening platforms for chemical toxicity testing. Their projects include developing an integrated microphysiological screening platform with "virtual human" models for assessing chemical toxicity, creating a microphysiological system with synthetic hemoglobin for mechanistic assessment of drug-induced liver injury, and developing a perfused organ panel as an animal surrogate for chemical toxicity testing. These grants, ranging from approximately $900,000 to support specific research initiatives, demonstrate Lena Biosciences' expertise in creating advanced in vitro testing systems that can replicate human cellular responses, assess potential drug and chemical toxicities, and potentially reduce the need for animal testing. The company collaborates with various academic institutions and experts in toxicology, pharmacology, genome biology, and tissue engineering to advance these sophisticated screening technologies.
Quick answers
Is Lena Biosciences, Inc. registered in SAM.gov?
Yes. Lena Biosciences, Inc.'s SAM.gov registration is active through October 9, 2027.
What is Lena Biosciences, Inc.'s most recent federal award?
Lena Biosciences, Inc.'s most recent federal grant award is An integrated MPS platform with "virtual humans" for chemical toxicity testing - people are exposed to diverse… (R44ES036492), from National Institute of Environmental Health Sciences (NIH), on August 22, 2024.
On GovTribe
See Lena Biosciences, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors